ACCβ Inhibitors

ACCβ inhibitors encompass a group of chemicals that can inhibit the activity of ACCβ, a key enzyme involved in fatty acid synthesis, through various mechanisms. These inhibitors, such as ND-630, CP-640186, and Soraphen A, act directly by binding to and inhibiting ACC enzymes, including ACCβ, disrupting the conversion of acetyl-CoA to malonyl-CoA. Other chemicals, such as TOFA and C75, indirectly inhibit ACCβ by targeting fatty acid synthesis pathways, reducing the demand for malonyl-CoA, and thereby inhibiting ACC activity. Compounds like AICAR and A-769662 exert their inhibitory effects on ACCβ by activating AMP-activated protein kinase (AMPK), which phosphorylates and inhibits ACC, reducing its carboxylase activity in response to cellular energy levels.

Fatostatin and T3 indirectly inhibit ACCβ by modulating the sterol regulatory element-binding protein (SREBP) pathway and thyroid hormone signaling, respectively, resulting in decreased ACCβ expression. Glucagon and Compound C indirectly inhibit ACCβ by activating protein kinase A (PKA) and AMPK, respectively, leading to phosphorylation and inhibition of ACC. Additionally, chemicals like DNP uncouple oxidative phosphorylation, increasing energy expenditure and indirectly reducing ACCβ activity due to energy depletion. These ACCβ inhibitors offer valuable tools for studying and regulating fatty acid synthesis and related metabolic processes, providing insights into strategies for metabolic modulation and research applications.